CIM
TBPH icon

Cambria Investment Management’s Theravance Biopharma TBPH Stock Holding History

Cambria Investment Management’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-216
Closed -$3K – 276
2014
Q4 		$3K Buy
+216
New +$3.76K ﹤0.01% 222

Other funds holding TBPH

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
FAM
Foundation Asset Management White Plains, New York $116M AUM 31.02% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Cambria Investment Management's TBPH Position: Q1 2015 in Review

Cambria Investment Management sold out of Theravance Biopharma (TBPH) in Q1 2015, closing a stake of 216 shares — an estimated $3K sold.

Cambria Investment Management first reported a position in TBPH in Q4 2014 and held it in 1 quarter. The position peaked at $3K in Q4 2014. 89 funds tracked by Wall St. Rank hold TBPH as of Q1 2015.

  • Cambria Investment Management reported no remaining Theravance Biopharma position as of Q1 2015 after selling out during the quarter.
  • Cambria Investment Management sold 216 Theravance Biopharma shares in Q1 2015, an estimated $3K.
  • Cambria Investment Management first reported a position in Theravance Biopharma in Q4 2014 and held it in 1 quarter.
  • Cambria Investment Management's Theravance Biopharma position peaked at $3K in Q4 2014.
  • 89 funds tracked by Wall St. Rank held Theravance Biopharma as of Q1 2015.

Based on Cambria Investment Management's 13F filing for Q1 2015, filed 2 Nov 2015.